EverHealth Weekly Issue 05

Everhealth Institute

The Weekly Briefing

The Everhealth Weekly

Evidence-based intelligence for preventing chronic disease and extending healthspan.

Issue 05 Monday · August 24, 2026

Good morning,

This summer’s strongest studies keep circling one uncomfortable idea: the numbers that actually decide your risk are mostly not the ones your annual physical collects. A 259,000-person analysis published this month found that where your fat sits predicts heart disease far better than what you weigh. A randomized trial found that inflammation fell before the weight did. And in human muscle tissue, roughly half the molecular signature we call “aging” turned out to depend on training status rather than birthdays.

The fourth study is the one that keeps the other three honest: when researchers gave 1,065 older adults the same prevention advice but built only half of them a structure to follow it, the structured group’s cognition improved about 55% more. Measurement is the easy part. Below: what to measure, and what to do about it.

— The Everhealth Institute team

1

This Week in the Evidence

Curated research roundup · what’s new, and what it means

Emerging — pooled cohort

Where your fat sits predicts heart disease better than what the scale says

Pooled prospective cohorts · 259,388 adults · median 20 years · JACC, August 2026

Researchers pooled 15 NIH- and NHLBI-funded cohorts — 259,388 adults with no coronary disease at baseline — and followed them a median of 20 years, asking whether two tape-measure numbers add anything beyond BMI across nine cardiovascular outcomes. They add a great deal. Among people whose BMI read completely normal, 5% still had an elevated waist circumference and 18% had an elevated waist-to-hip ratio — and that hidden central fat carried 15% to 50% higher risk across most of the nine outcomes. Among adults with obesity, central adiposity accounted for 46% of atrial fibrillation events, 49% of heart failure events, and 36% of coronary heart disease deaths.

The authors’ own summary is the quotable part: waist circumference and waist-to-hip ratio “reclassify risk defined by traditional BMI thresholds.” In plain terms — BMI put a large group of people in the wrong box, and a tape measure moved them out of it.

Clinical takeaway: BMI was never designed to describe an individual. It cannot distinguish muscle from fat, and it cannot see where fat is stored — which is the part that matters, because visceral fat wrapped around the organs behaves like an active endocrine organ, not inert padding. This is the evidence behind the phrase “normal weight, high risk.” A tape measure costs nothing and takes fifteen seconds; a DEXA body composition scan answers the same question with far more precision, separating visceral fat, subcutaneous fat, lean mass and bone. Either one tells you more than the number you are currently handed. Caveats: this is observational, adiposity was measured once at baseline, and the cohorts lacked physical activity, diet and genetic-risk data.

Source: Dardari ZA, Blaha MJ, et al. Risk Reclassification Beyond BMI by Waist Circumference and Waist-to-Hip Ratio Across Nine Cardiovascular Outcomes. JACC. 2026;88(6):670–684. ACC announcement → · Full results summary →

Strong — randomized trial

Semaglutide cut inflammation by nearly 40% — and it happened before the weight came off

Prespecified secondary analysis of the SELECT randomized trial · 17,604 adults · Circulation, August 18, 2026

SELECT randomized 17,604 adults with established cardiovascular disease and overweight or obesity — but not diabetes — to semaglutide or placebo. This prespecified analysis, published four days ago, asked what happened to hs-CRP, the standard blood marker of low-grade inflammation. Two findings stand out. First, baseline hs-CRP independently predicted future heart attacks, strokes and cardiovascular deaths — in every subgroup examined. Second, semaglutide lowered hs-CRP by roughly 38% at two years, across every baseline inflammation stratum, and the drop appeared before most of the weight loss and independent of changes in cholesterol. Larger reductions tracked with better outcomes.

Clinical takeaway: Two practical points. hs-CRP is an inexpensive, universally available blood test that carries risk information your lipid panel does not — and most adults have never had it drawn. It belongs alongside Lp(a) on the short list of tests that change a prevention plan. And the GLP-1 story is now clearly bigger than weight: these drugs appear to act on the inflammatory biology of atherosclerosis itself, which is a different mechanism than “you lost 15% of your body weight.” Important limit: this remains a biomarker analysis. It shows that inflammation fell and that the fall tracked with outcomes — it does not prove that lowering CRP is what produced the benefit.

Source: Plutzky J, Ridker PM, Lincoff AM, et al. Effect of Semaglutide on High-Sensitivity CRP in SELECT: A Prespecified Secondary Analysis. Circulation. August 18, 2026. Read the study →

Early — mechanistic

In trained muscle, half the molecular signature of aging simply isn’t there

Human muscle biopsy multi-omics · young vs. older, trained vs. untrained · Nature Aging, July 2026

Researchers took skeletal muscle biopsies from young and older adults sorted by training status — at rest and after a bout of exercise — and profiled them across transcriptomics, lipidomics and metabolomics. In sedentary older adults they found the expected molecular fingerprint of aging. In trained older adults, roughly half of those age-related differences were absent altogether; their muscle profiles partly resembled those of young, active people, with preserved expression of the genes governing cellular respiration and energy metabolism. Fitter older participants also mounted a larger molecular response to a single exercise session — meaning the machinery that adapts to training stays switched on.

Clinical takeaway: Chronological age set the expectation; training status changed what was actually in the tissue. Treat this as mechanism, not proof — it compares trained to untrained people rather than randomizing them, so decades of other habits are baked into the trained group. But it puts molecular detail underneath something we already act on clinically: muscle is not a passive tissue you lose with age, it is a metabolic organ whose biological age you can negotiate with. The currency is years of consistent aerobic base work and resistance training — not a supplement.

Source: Janssens GE, Trętowicz MM, Grevendonk L, et al. Delayed molecular aging, preservation of energy metabolism and enhanced exercise response in exercise-trained human muscle. Nature Aging. 2026;6(7):1482–1500. Read the study →

Strong — randomized trial

A two-year lifestyle program improved cognition — and the structure was the active ingredient

Randomized controlled trial · 1,065 at-risk older adults · 12 sites, 11 countries · 2 years · The Lancet, July 2026

LatAm-FINGERS randomized 1,065 older adults at elevated dementia risk, across 11 Latin American countries, to one of two versions of the same advice. The structured arm (n=539) received supervised exercise, adapted MIND-diet nutrition counseling, computerized cognitive training, cardiovascular risk monitoring, and 38 group meetings over two years. The flexible arm (n=526) received the same general recommendations as periodic health education — four meetings, no ongoing coaching. After two years, the structured arm improved about 55% more on a global cognition composite, with significant gains in memory, executive function and processing speed.

Clinical takeaway: Notice what was being compared. Both groups were told what to do. Only one was built a system to do it inside. That gap — 38 meetings against four — is the finding, and it is the most useful thing any of us learned this summer about behavior change. It also replicates the Finnish FINGER and US POINTER results in a far more diverse, lower-resource population, which is how a promising result graduates to a durable one. Caveats: two years is short, the endpoint is a cognitive test composite rather than dementia diagnoses, and “55% greater improvement” is a relative difference between two active arms — not a 55% reduction in dementia.

Source: Crivelli L, et al. Multidomain lifestyle intervention for prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial. The Lancet. Published online July 13, 2026. Read the study → · AAIC 2026 summary →

2

The Long View

Original perspective · one idea, examined

The Long View

The measurements your annual physical still doesn’t take

A standard annual physical in 2026 produces a remarkably short list of numbers: weight, blood pressure, a lipid panel, a metabolic panel, a blood count. It is a good list. It is also, in a real sense, a list from 1985 — assembled when those were the things we could measure cheaply, and left largely undisturbed since. Nearly everything interesting in this summer’s evidence falls just outside it.

Start with weight. The JACC data are blunt: among adults whose BMI reads normal, nearly one in five carries an elevated waist-to-hip ratio, and that hidden central fat raises cardiovascular risk 15 to 50 percent. Nothing in a standard visit catches it — not because the measurement is difficult, but because nobody reaches for the tape. In people who do carry obesity, central fat accounted for roughly half of all heart failure and atrial fibrillation events. The scale was never measuring the thing that mattered. It was measuring a proxy for it, badly.

Then inflammation. hs-CRP costs a few dollars, and in SELECT it predicted heart attacks and strokes independent of body weight and independent of LDL cholesterol — yet it is absent from most annual panels. The same is true of Lp(a), which the March 2026 lipid guideline now says every adult should have measured once in a lifetime. These are not experimental assays. They are ordinary blood tests that simply have not been added to the habit.

And then age itself. The muscle biopsy work is the most striking version of this. We record chronological age on every chart as though it were a measurement. It is not; it is a birthday. In trained older adults, half the molecular signature we would call “aging” was not present in the tissue. The chart said one thing. The muscle said another.

There is a version of this argument that curdles into a sales pitch for testing everything, and that is not the argument. LatAm-FINGERS is the corrective. Both arms of that trial knew exactly what to do — eat this way, move this much, manage blood pressure. Only one arm had a structure for doing it, and the difference between 38 meetings and four is what produced the cognitive benefit. Measurement without a system to act on it changes nothing. It just yields a more detailed record of what went wrong.

So the useful frontier is narrower, and less glamorous, than “more data.” It is this: measure the handful of things that genuinely reclassify your risk — where your fat sits, how inflamed you are, what your Lp(a) is, how strong you are, how fit you are — then build the structure that acts on them, then re-measure to find out whether it worked. That is not a longer list than the one you get today. It is a different one, attached to a plan. Your annual physical will not hand it to you. You have to ask for it.

3

Do This Week

Plain-language, practical prevention

  • 1Take a tape measure to your waist — today. Measure at the top of your hip bone, at the end of a normal exhale, without pulling the tape tight. Then divide that number by your height in the same units. A waist-to-height ratio under 0.5 is the simple, widely used target: your waist should be less than half your height. It costs nothing, takes fifteen seconds, and per this month’s JACC data it tells you something your bathroom scale cannot.
  • 2Ask for two blood tests you have probably never had: hs-CRP and Lp(a). hs-CRP measures the low-grade inflammation that predicted cardiovascular events in SELECT independent of weight and cholesterol. Lp(a) is inherited, needs measuring only once in a lifetime, and is invisible on a standard lipid panel. Both are inexpensive, both are widely available, and both change what a reasonable prevention plan looks like.
  • 3Lift twice a week — and count it as metabolic and brain work, not just muscle. Trained older adults were missing roughly half the molecular hallmarks of aging in their muscle tissue. Two sessions a week of compound movements — squats, rows, presses, loaded carries — is the dose most people can actually sustain. What produced the effect was years of consistency, not intensity in any single session.
  • 4Build the structure, not the intention. The clearest lesson from LatAm-FINGERS is that both groups knew the right answer; only one had a system. Put your training sessions on the calendar as appointments. Schedule the lab draw before you leave the office. Set the recheck date now, while you are motivated. A plan you cannot skip beats a plan you merely agree with.
4

Questions We Got This Week

Straight answers to what patients actually asked

Is waist-to-height ratio really better than BMI?

For predicting cardiovascular risk, the evidence increasingly says yes — because it captures where fat is stored, and visceral fat around the organs is metabolically active in a way that fat under the skin is not. The August 2026 JACC analysis of 259,388 adults found that waist circumference and waist-to-hip ratio reclassified risk beyond BMI thresholds, including in people whose BMI looked entirely normal. BMI remains useful for describing populations. It is a weak tool for describing one person, and a DEXA body composition scan is the precise version of the same question.

What is a normal hs-CRP, and what does a high one mean?

hs-CRP is generally interpreted in bands: below 1.0 mg/L is low cardiovascular risk, 1.0–3.0 mg/L is average, and above 3.0 mg/L is high. A single elevated value is not a diagnosis — any recent infection, injury, or flare of an inflammatory condition will raise it, so a high result should be repeated a few weeks later before it is acted on. What makes it worth measuring is that it carries risk information independent of your cholesterol and your weight, which means it can change a prevention plan that a lipid panel alone would leave unchanged.

Can you actually reverse muscle aging, or just slow it down?

Honestly: we do not yet know which of those two words is correct, and anyone who tells you otherwise is ahead of the data. What the July 2026 Nature Aging work shows is that trained older adults were missing roughly half the molecular differences that distinguish old muscle from young muscle — a cross-sectional comparison, not a randomized training study, so it cannot separate “training reversed this” from “these people trained for decades.” What is not in doubt is the direction: resistance and aerobic training measurably improve muscle mass, strength, mitochondrial function and VO₂ max at every age tested, including in the ninth decade of life.

On the radar: the European Society of Cardiology Congress runs August 28–31 in Munich, with 59 late-breaking trials — among them STAREE, a randomized trial of statins for primary prevention in healthy adults over 70. We will cover what matters in next week’s issue.

Medical disclaimer: The Everhealth Weekly is for general educational purposes and reflects the evidence available at publication. It is not individualized medical advice and does not create a physician–patient relationship. Always consult your own clinician before changing your care, medications, or lifestyle.
Everhealth Institute
Precision · Restorative · Regenerative Medicine
Pushing the frontier of evidence-based chronic disease prevention.
everhealthinstitute.com
You’re receiving this because you subscribed at everhealthinstitute.com · Manage preferences · Unsubscribe

Ready to Begin Your
Health Journey?

Your personalized program starts with a comprehensive assessment.